OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedUnitedHealthcarePolicy CS103TN.T

Prolotherapy and Platelet Rich Plasma Therapies (for Tennessee Only)

Customize your policy alerts

Sign up for UnitedHealthcare Policy CS103TN.T alerts

Get alerted when Policy CS103TN.T changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This Tennessee Medicaid/CoverKids medical policy governs use and coverage determination for prolotherapy and platelet-rich plasma (PRP) therapies for beneficiaries in Tennessee.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Tennessee Only)

Policy CodePolicy CS103TN.T

Change TypeUpdated clinical evidence and referencesprevious version archived

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionWhen requesting PRP or prolotherapy, submit prior authorization with documentation of failed conservative therapy, detailed PRP/preparation or prolotherapy protocol, and targeted outcome measures.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information.

2therapies declared not medically necessary

5 codesprocedure/HCPCS/CPT codes listed

multiple small/low-quality studiesevidence limited/heterogeneous

Tennesseestate-specific applicability

13NNH (foot/ankle PRP)

Coverage Criteria and Evidence Summary

inv-01: Not Medically Necessary — Unproven and not medically necessary

Unproven and not medically necessary

Primary policy stance: Prolotherapy and platelet-rich plasma are considered unproven and not medically necessary for any condition or indication.

Applies to all indications covered by Tennessee Medicaid/CoverKids under this policy (see Application).

inv-02: Summary criteria and evidence implications — Evidence-based coverage considerations

Evidence-based coverage considerations (summarized from RCTs and systematic reviews in these chunks):

Clinical context: Treatment considered for knee osteoarthritis (typically Kellgren-Lawrence grade 2–3) and chronic lateral epicondylosis refractory to conservative care.

Multiple RCTs and systematic reviews evaluated these populations.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Tennessee Only)

Policy CodePolicy CS103TN.T

Change TypeUpdated clinical evidence and referencesprevious version archived

Effective DateFeb 1, 2026

Next Review DateN/A

SourceLink

On This Page

Evidence strength for KOA: Randomized trials and systematic reviews report mixed results: some small RCTs and meta-analyses report short-term pain/function improvements with dextrose prolotherapy or PRP versus saline or physiotherapy, while larger syntheses note limited or no clinically significant benefit versus saline and highlight methodological heterogeneity.

References include individual RCTs and systematic reviews/meta-analyses.

Evidence strength for lateral epicondylosis: Longer-term RCT data (up to 24 months) and pooled analyses show prolotherapy and PRP may improve pain and function versus physiotherapy or saline in some studies, but overall certainty is limited by small trials and heterogeneity.

See 24-month RCT and 12-week RCTs reporting clinically relevant DASH/Q-DASH and VAS improvements.

Common limitations: Frequent limitations include small sample sizes, short follow-up durations, heterogeneous injection protocols (concentration, leukocyte content, volume), variable comparators, and potential placebo/needling effects.

These limitations reduce generalizability and certainty of benefit.

Coverage implication: Because evidence is heterogeneous and of limited quality, selective coverage may be considered only in well-documented, refractory cases with clear protocol and outcome measurement; routine use is not supported by high-certainty evidence.

Synthesis of RCT and systematic review conclusions.

inv-03: Coverage with criteria (provisional) — Covered when ALL of the following are met

Covered when ALL of the following are met

Base criteria: 1) Diagnosis of the targeted musculoskeletal condition documented by clinical assessment (examples: lateral epicondylitis, rotator cuff tendinopathy, temporomandibular joint disorder, selected soft-tissue injuries). 2) Persistent symptoms despite an adequate trial of conservative care (structured home exercise program, physical therapy, splinting, and appropriate pharmacologic therapy) documented in the record. 3) Provider documents the specific treatment protocol (for prolotherapy: dextrose concentration, injection sites, number and timing of injections; for PRP: preparation method including leukocyte content, platelet concentration if available, volume, number/timing of injections) and the planned outcome measures (e.g., VAS, DASH/QuickDASH, WOMAC, AOFAS).

Trials generally enrolled patients refractory to first-line treatments and required documentation of protocol and outcomes.

inv-04: Evidence-based coverage statements — Evidence summaries and RCT results

Evidence summaries and RCT results — applicability and limitations

TMJ disorders (prolotherapy): Systematic reviews and RCTs demonstrate dextrose prolotherapy reduces TMJ pain (VAS) versus placebo in multiple small trials; effects on maximal incisal/mouth opening are inconsistent and long-term data are limited.

Several meta-analyses and RCTs report pain reduction but small sample sizes and heterogeneity limit certainty.

Lower-limb tendinopathies: Observational studies report symptom improvement after prolotherapy or sclerotherapy for Achilles tendinopathy; controlled RCT evidence is limited and heterogeneous for Achilles and plantar fasciitis, with mixed results for PRP versus corticosteroid or other comparators.

Evidence limited by small trials and variable protocols.

PRP for knee osteoarthritis: Systematic reviews/meta-analyses show mixed results: some RCTs report PRP superiority over HA or saline at certain timepoints (6–12 months), whereas a large high-quality RCT found no difference versus saline at 12 months; lack of PRP standardization and variable blinding affect applicability.

Evidence remains inconclusive for routine use in KOA.

inv-05: Summary of evidence-based coverage considerations

Consider coverage only when criteria addressing indication specificity, prior conservative therapy, and procedural details are met, because evidence is inconsistent and heterogeneous.

Patient selection and prior therapy: Patient has a specific diagnosis with documented severity (e.g., Kellgren-Lawrence grade for KOA) and has failed or is intolerant to standard conservative therapies (exercise/physical therapy, NSAIDs, corticosteroid or hyaluronic acid injections when appropriate).

Systematic reviews and guidelines emphasize conservative therapy first and selection of refractory patients for biologic interventions.

Procedural documentation: Provider documents PRP preparation (leukocyte-rich vs leukocyte-poor, platelet concentration if available), number and timing of injections, imaging guidance when used, and informed consent including counseling on risks (including higher post-injection pain rates in certain indications).

Heterogeneity of PRP protocols is a major limitation to generalizability.

Condition-specific expectations: For knee OA and hip OA, evidence is variable and professional guidance differs (AAOS cautious for KOA; AAHKS and ACR recommend against routine use in advanced arthritis); for tendinopathies and lateral epicondylitis some trials show benefit but certainty is low; for wounds (DFU) evidence suggests possible benefit but overall heterogeneity reduces confidence.

Use these nuances when assessing anticipated benefit and coverage decisions.

inv-06: Condition-level evidence summaries

Evidence-based findings and comparative effectiveness summaries by condition

Foot and ankle (Achilles, plantar fasciitis, OCLs): PRP shows mixed efficacy across foot/ankle conditions; some meta-analyses report greater pain improvement for plantar fasciitis versus corticosteroid or placebo, but PRP is associated with higher rates of transient post-injection pain and an estimated number needed to harm of 13 in foot/ankle trials.

Safety signals and heterogeneity in protocols limit routine coverage.

Rotator cuff and shoulder: Systematic reviews report short-term pain reduction and some transient functional benefits for PRP in rotator cuff conditions, but long-term benefits are inconsistent and evidence quality is low to very low.

AAOS guidance does not support routine use for many shoulder indications.

Lateral epicondylitis: Randomized trials and meta-analyses provide mixed results: some studies show clinically meaningful improvements in pain and function from 4 to 52 weeks, while others show comparable outcomes to saline or steroids; overall certainty is low.

Select refractory patients may derive benefit per some RCTs.

Osteochondral lesions of the talus (adjunct to microfracture): Small RCTs show no consistent statistically significant added benefit of PRP as adjunct to microfracture for talar OCLs, though trends toward improved AOFAS scores have been reported in small studies.

Evidence limited by small sample sizes and lack of masking.

Low back pain: Evidence from small RCTs and network meta-analyses is mixed: PRP may be comparable to corticosteroid or lidocaine for short-term pain reduction and may show some disability improvement at intermediate timepoints in small studies, but results are inconsistent and limited by small sample sizes.

Insufficient high-quality evidence to draw definitive conclusions.

inv-07: Foot osteochondral lesion adjunct therapy

Foot (talar OCL) — adjunct therapy after arthroscopic microfracture

RCT evidence: A small prospective, blinded RCT (n=40) comparing PRP, hyaluronic acid, and saline as adjuncts after arthroscopic microfracture reported greater AOFAS and VAS improvements in the PRP group at 15 months, but the study was limited by small sample size, short follow-up and lack of participant masking.

Suggests potential adjunct benefit but insufficient evidence for firm conclusions.

inv-08: Low back pain — assorted indications

Low back pain — multiple indications (chronic nonspecific LBP, discogenic pain, facet joint syndrome, SIJ pathology, prolapsed disc): evidence mixed with small RCTs and meta-analyses.

Network/meta-analysis findings: A network meta-analysis of 4 RCTs (n=154) found corticosteroid had better short-term pain reduction at 4 weeks; PRP showed comparable effects to corticosteroid and lidocaine at several timepoints and some signals of improved disability at 6 months but evidence is limited by few small trials.

Small number of studies and participants limits confidence.

Intradiscal and peridiscal PRP: Prospective trials of intradiscal PRP report improvements in pain and function up to 48 weeks in small uncontrolled or limited RCTs, but lack of standardized PRP composition and small sample sizes reduce generalizability.

Promising but not definitive; further RCTs needed.

Facet/SIJ injections: Small RCTs suggest PRP may provide longer-duration efficacy than corticosteroid/local anesthetic for facet or SIJ injections in some studies, but sample sizes and follow-up are limited.

Evidence remains inconclusive for routine adoption.

inv-09: Wounds — DFU/VLU/other chronic wounds

Wounds — diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, pilonidal sinus: systematic assessments show possible benefit for DFUs; evidence for VLUs and other chronic wounds is inconclusive.

Diabetic foot ulcers (DFU): Multiple systematic reviews and technology assessments report that autologous PRP added to standard wound care may increase complete wound closure and shorten time to closure in DFUs (moderate to low strength of evidence), but heterogeneity in protocols reduces certainty.

ECRI and Hayes assessments support potential benefit for DFU but recommend further standardized trials.

Venous leg ulcers and other chronic wounds: Evidence for VLUs and pressure ulcers is inconsistent and insufficient for routine recommendation; some small RCTs report benefit but overall data are heterogeneous and low quality.

Hayes and other reviews call for larger, standardized trials.

Adjuncts and small surgical wound studies: Small RCTs (eg, pilonidal sinus, PRF adjuncts) report faster recovery or histologic changes but are limited by size and methodological variability and do not establish routine clinical benefit.

Promising signals require confirmation in larger studies.

inv-10: Guideline recommendations (AAOS) — Professional guideline statements

Professional guideline statements

AAOS knee OA guidance: AAOS (2022) states PRP may reduce pain and improve function in symptomatic knee OA based on low-quality evidence and recommends further research with better OA characterization.

Supports cautious, limited use in knee OA within research or well-characterized subgroups.

AAOS shoulder/rotator cuff: AAOS guidance (2019, 2020) does not support routine use of PRP for glenohumeral OA or for nonoperative rotator cuff management; limited evidence does not support biological augmentation for routine rotator cuff repair outcomes.

Routine use not recommended for these shoulder indications.

Other society positions: AAHKS (2019) recommends against biologics including PRP for advanced hip/knee arthritis; ACR strongly recommends against PRP for knee/hip OA; NICE (2019) allows PRP only with special arrangements for governance, consent, and audit or research.

Professional recommendations vary but generally counsel caution and research governance.

inv-11: Indication-based coverage conclusions

Coverage stance varies by indication and is tied to the strength and quality of evidence; summarize as distinct groups below.

Chronic wounds (including DFU/VLU): Autologous PRP: evidence is inconclusive for chronic wounds in general; some trials and meta-analyses suggest benefit for diabetic foot ulcers (moderate SOE) but overall study heterogeneity and variable protocols limit routine coverage.

ECRI and Hayes assessments indicate possible DFU benefit but call for standardized trials.

Knee osteoarthritis (KOA): Evidence quality is inconsistent: some RCTs and meta-analyses report benefit of PRP over HA or saline at certain timepoints, but larger trials and guideline statements differ; NICE recommends use only within research/governance arrangements and ACR recommends against routine use.

Coverage decisions should consider guideline positions and requirement for governance/research when applicable.

Hip and advanced knee arthritis: Professional societies (AAHKS) do not recommend biologics including PRP for routine treatment of advanced hip or knee arthritis due to unproven benefits and safety/cost concerns.

Routine coverage for advanced arthritis is not supported.

Rotator cuff and other tendinopathies: Evidence for PRP and prolotherapy across tendinopathies is mixed; some individual trials show benefit, but systematic reviews grade certainty as low to very low and do not support routine use without better-quality evidence.

Selective coverage may be considered in refractory cases with protocol documentation.

Other indications: For indications with insufficient or conflicting evidence (eg, many soft-tissue injuries, certain foot/ankle conditions), coverage should be limited to research settings or require detailed justification and documentation of prior conservative therapy failure.

Policy stance depends on indication-specific evidence strength.

No indication-specific exceptions are provided in this policy. Both prolotherapy and platelet-rich plasma (PRP) are designated as unproven and not medically necessary for any condition or indication under Tennessee Medicaid/CoverKids, consistent with the Coverage Rationale in the policy.

Multiple trials and systematic reviews excluded patients with clear alternative pathology or contraindications; common exclusions reported in the evidence base include joint effusion, active infection, and patients outside the typical Kellgren‑Lawrence severity spectrum used in many KOA trials (generally grade 2–3). When assessing trial eligibility or prior-therapy requirements for coverage consideration, document prior conservative care and ensure the patient population and disease severity match those studied in the cited trials.

Some shoulder-focused trials reported inferior outcomes for dextrose prolotherapy compared with corticosteroid injections for bursitis/rotator cuff–related pain: systematic reviews note that DPT resulted in worse physical performance outcomes versus corticosteroid in shoulder/bursitis indications, and rotator cuff surgery studies found minimal incremental benefit from PRP. These findings support caution for prolotherapy in selected shoulder indications.

The evidence base frequently lacks standardized, reproducible PRP preparations and in many studies prolotherapy or PRP procedures were performed without thorough documentation of prior conservative therapy. Procedures using undocumented or nonstandardized PRP formulations (no report of leukocyte content, platelet concentration, activation method, volume, or injection timing) or prolotherapy delivered without clear documentation of prior failed conservative treatments are noted as situations where coverage or medical-necessity justification may be limited.

For hip osteoarthritis, systematic assessments conclude evidence does not support routine PRP use. A Hayes HTA identified small, low-quality RCTs and found no clear advantage of PRP over hyaluronic acid; overall the evidence does not demonstrate clinically meaningful benefit beyond placebo at follow-up intervals up to 6–12 months, and routine use for hip OA is therefore not supported by the cited literature.

Across clinical indications, high-quality data are limited. PRP preparations are heterogeneous and lack standardization, and many trials have small sample sizes, inconsistent outcome reporting, and short follow-up. These methodological limitations reduce the certainty of effect estimates and limit generalizability of positive signals reported in some small trials and meta-analyses.

The policy does not list explicit procedural exclusions, but multiple evidence reviews and HTAs conclude insufficient high-quality evidence to support routine use of PRP or prolotherapy for many indications. In practice, absence of standardized protocols and limited evidence may justify excluding or denying coverage unless clear documentation addressing indication, prior conservative care, and product preparation is provided.

Professional society guidance cited in the policy does not support routine biologic injections for advanced hip or knee arthritis. The American Association of Hip and Knee Surgeons (2019) states biologic therapies including PRP are not recommended for treatment of advanced hip or knee arthritis, and the American College of Rheumatology/Arthritis Foundation (2019) strongly recommends against PRP for knee and hip osteoarthritis.

This Medical Policy is provided for informational purposes and does not constitute medical advice. Coverage determinations remain subject to applicable federal, state, or contractual benefit plan requirements, which govern in the event of a conflict. UnitedHealthcare may modify policies and recommends review of plan-specific terms prior to determining coverage.

The core coverage position in this policy is that prolotherapy and platelet-rich plasma are unproven and not medically necessary for any condition or indication under Tennessee Medicaid/CoverKids. This stance applies broadly across musculoskeletal, wound, and soft-tissue indications addressed in the evidence synthesis.

Systematic reviews and randomized trials for knee osteoarthritis report mixed findings. Some meta-analyses and small RCTs suggest short‑term symptom improvement with dextrose prolotherapy or PRP versus comparators, but larger, higher-quality trials (for example, a 288‑participant RCT of PRP vs saline) found no significant difference at 12 months. Overall, reviews characterize the evidence as limited, heterogeneous, and of low certainty for routine use in KOA.

Many reported studies are small, uncontrolled, or heterogeneous in patient selection, injection technique, PRP composition, and outcome measures, with follow-up commonly ≤12 months. These factors limit the confidence of pooled estimates and interpretation of long‑term benefit across indications.

A large, participant- and assessor‑blinded RCT (Bennell et al., n = 288) evaluating intra-articular leukocyte‑poor PRP versus saline placebo in mild‑to‑moderate knee osteoarthritis found no statistically significant difference in pain or medial tibial cartilage volume at 12 months, underscoring the lack of demonstrated benefit in a well-designed, larger trial.

Systematic reviews evaluating soft‑tissue and tendon indications consistently report insufficient, low‑quality, or conflicting evidence. Cochrane and more recent meta-analyses conclude that PRP does not have robust evidence of clinically meaningful long-term benefit for many soft‑tissue injuries, and routine use is not supported by the cited literature.

Long‑term benefits are uncertain across indications; evidence certainty is often rated low or very low due to study limitations, imprecision, and inconsistency. Positive short‑term signals are not consistently sustained and optimal patient selection and preparation methods are not established.

For chronic wounds, evidence is inconclusive overall. Systematic reviews and meta-analyses report that autologous PRP may increase complete closure rates for diabetic foot ulcers (moderate to low strength of evidence in some analyses), but results are heterogeneous and evidence for venous leg ulcers and other chronic wound types is insufficient to support routine use.

Guideline statements summarized in the policy provide strong recommendations against routine PRP use in osteoarthritis: the American College of Rheumatology/Arthritis Foundation strongly recommends against PRP for knee and hip osteoarthritis, and other professional groups (AAOS, AAHKS) advise caution or limit recommendations pending higher-quality evidence.

Because the policy designates these therapies as unproven and not medically necessary for any indication, requests for prolotherapy or PRP should be denied unless the requesting documentation convincingly demonstrates alignment with narrowly defined, evidence‑based exceptions (if any) and includes detailed prior conservative treatment history, explicit PRP preparation data, and clear expected outcome measures.

Prior Authorization, Documentation, and Step Therapy Guidance

Prior Authorization

Prior authorization expectation — therapies unproven and not medically necessary

For Tennessee Medicaid/CoverKids, prolotherapy and platelet-rich plasma (PRP) are classified as unproven and not medically necessary for any condition or indication; requests for these services are therefore expected to be denied absent compelling justification or plan-specific terms that override this stance.

Prior Authorization

Prior authorization recommended for DPT/PRP injectables

Consider prior authorization when requesting dextrose prolotherapy (DPT), PRP, or other injectable biologic therapies for knee osteoarthritis or chronic lateral epicondylitis; authorization requests should include documentation that supports the clinical indication and prior treatments.

Prior Authorization

Require documentation of prior conservative (refractory therapy) trial

Prior authorization requests should include evidence of prior first-line conservative care (e.g., structured home exercise, physical therapy, splinting) and a clinical rationale for proceeding to prolotherapy or PRP in refractory cases.

Prior Authorization

Prior authorization advised for PRP/prolotherapy due to heterogeneity

When PRP or prolotherapy is proposed, prior authorization is advised because heterogeneity of evidence and lack of standardized preparations justify review with supporting documentation of indication, prior therapies, and product/protocol details.

Prior Authorization

Require detailed PRP/procedure protocol and failed conservative therapy

Prior authorization requests should require documentation of failed conservative therapy, the specific PRP preparation and injection protocol (including leukocyte content, concentration, volume), target tissue/diagnosis and severity, and the intended number and timing of injections.

Prior Authorization

Prior authorization for PRP injections — require indication, prior treatments, and PRP details

Because evidence across indications is heterogeneous and generally low to very low certainty, prior authorization should require documentation of the indication, prior treatments attempted/failed, and specific PRP/preparation details to justify medical necessity.

Prior Authorization

Require documented clinical rationale with prior authorization

Evidence reviews frequently note inconsistent results and lack of standardized PRP protocols; prior authorization should record the documented clinical rationale and expected benefits given this uncertainty.

Prior Authorization

Prior authorization likely for OA / advanced arthritis — follow society guidance

Specialty society statements find evidence insufficient or recommend against routine PRP in advanced hip/knee arthritis and for knee/hip OA; prior authorization is likely for OA and advanced arthritis to confirm indication, prior conservative therapy, and potential enrollment in trial/registry where applicable.

Note

No explicit prior authorization codes listed — use standard PA process

The policy does not list specific prior authorization CPT/HCPCS codes or unique prior authorization procedures; use the plan's standard prior authorization processes and reference the applicable procedure codes when submitting requests.

Step Therapy

Stepwise care — require conservative modalities before injectables

Evidence often compares prolotherapy to exercise, saline, or physiotherapy; consider a stepwise approach requiring prior conservative modalities such as structured exercise or physiotherapy before approving advanced injectables.

Step Therapy

Expect trial of exercise/physical therapy before injectables

Many trials administered prolotherapy alongside or after exercise programs; prior authorization or plan rules may require a documented trial of structured exercise/physical therapy before DPT is approved.

Step Therapy

Conservative therapy first — PRP considered only after conservative care fails

Evidence reviews recommend conservative therapies (oral medications, physical therapy) before considering PRP; PRP is generally considered when conservative therapies are contraindicated or have failed.

Step Therapy

Step therapy suggestion — failure/contraindication of standard treatments required

Require documentation that standard conservative treatments (physical therapy, NSAIDs, activity modification, and, where appropriate, corticosteroid or hyaluronic acid injections) have failed or are contraindicated before PRP or prolotherapy is authorized.

Step Therapy

Step therapy expectation for tendinopathies — conservative measures required first

For tendinopathies (e.g., lateral epicondylitis, plantar fasciitis), consider requiring failure of standard conservative measures including physical therapy, NSAIDs, activity modification, and, when appropriate, a trial of corticosteroid injection prior to PRP.

Step Therapy

Conservative comparators commonly used before PRP

Comparators in trials include corticosteroid, lidocaine, and standard wound care; many studies used these nonbiologic therapies before or instead of PRP, supporting their role as usual comparators and first-line options.

Step Therapy

Require conservative therapy first per ASIPP guidance

ASIPP guidance indicates regenerative therapies may be provided in conjunction with structured exercise and appropriate conventional care; payers may require evidence of prior conventional therapy before approving biologic injections.

Billing Rule

Coding reference — include listed procedure/HCPCS/CPT codes on claims

When submitting claims, reference the listed procedure and HCPCS/CPT codes (e.g., 0232T, G0460, G0465, M0076, P9020); listing does not imply coverage and may affect adjudication.

Documentation Required

Required clinical documentation — diagnosis severity, baseline scores, prior therapies

Clinical documentation should include diagnosis severity (for KOA, Kellgren-Lawrence grade 2–3 when applicable), baseline pain scores (e.g., VAS), prior conservative therapies tried, injection type/concentration/site, number of planned sessions, and planned follow-up outcome measures (WOMAC, OKS, PPT) to support effectiveness claims.

Documentation Required

Suggested documentation elements — diagnosis, prior response, protocol, outcome measures

Suggested documentation elements include the specific diagnosis (e.g., lateral epicondylitis, rotator cuff tendinopathy, TMJ disorder), prior conservative therapy and response, dextrose concentration and injection protocol (for DPT), and planned outcome measures (VAS, DASH/QuickDASH, SPADI, PRTEE).

Documentation Required

Suggested clinical documentation elements — objective measures and protocol details

Studies frequently used objective clinical measures such as maximal incisal/mouth opening (MIO/MMO), VAS pain scores, and clearly documented injection protocols and number of injections; include these objective baseline and follow-up measures when available.

Documentation Required

Required documentation elements — indication, prior therapy, PRP prep and injection plan

Required documentation elements for authorization should include the specific indication and grade/stage, prior conservative therapies attempted and their outcomes, PRP preparation method (leukocyte-rich vs leukocyte-poor, concentration, volume), number and timing of injections, use of imaging guidance, and counseling about possible post-injection pain.

Documentation Required

Required clinical documentation elements — include PRP preparation and outcome measures

Evidence summaries emphasize heterogeneity in PRP preparation and inconsistent reporting of adverse events; required clinical documentation should therefore include PRP preparation method, number/volume of injections, targeted diagnosis, prior conservative therapies tried, and objective baseline and follow-up outcome measures (e.g., VAS, AOFAS, ODI).

Documentation Required

Document PRP composition and selection (platelet/WBC counts, activation)

Document PRP composition when available (platelet and white blood cell counts, activation method) and the rationale for selecting a leukocyte-rich vs leukocyte-poor preparation, since many studies lacked these details and reviewers often cite this omission.

Documentation Required

Research/governance documentation for knee OA — enroll in governance/audit when applicable

For knee osteoarthritis, document whether PRP use is within a research, clinical governance, or audit arrangement and include informed consent reflecting uncertainty of long-term benefit and potential harms per NICE recommendations.

Documentation Required

Benefit plan governance — plan terms govern final coverage

When deciding coverage or approving requests, reference applicable federal, state, or contractual benefit plan terms; the Medical Policy is informational and plan-specific terms govern final coverage decisions.

Denial Risk

Coverage denial trigger — therapies unproven and not medically necessary

Prolotherapy and PRP are explicitly listed as unproven and not medically necessary for any condition or indication; absent documented, compelling, indication-specific evidence and conformity with plan terms, denial of coverage is a likely outcome.

Denial Risk

Evidence limitations may prompt denial — heterogeneous designs and techniques

Heterogeneous study designs, variable injection techniques and concentrations, and limited high-quality evidence are recurring limitations that may prompt denial or requests for further justification supporting medical necessity.

Denial Risk

Evidence gaps affecting authorization — small/short trials and limited comparators

Lack of well-designed comparative studies, small sample sizes, heterogeneous populations, and short follow-up durations reduce certainty of benefit and may result in denial when robust long-term effectiveness or comparative data are required.

Denial Risk

Standardization and efficacy concerns — lack of standardized PRP prep may trigger denial

Because PRP preparations are not standardized and efficacy/safety data are inconsistent (including trials showing no difference vs saline), reviewers may deny coverage or require strong justification when preparation or outcome data are not provided.

Denial Risk

Heterogeneous evidence may trigger denial — variable protocols and reporting

Heterogeneous PRP preparation, injection methods, and variable number/timing of injections are cited repeatedly; absence of protocol standardization and missing documentation on preparation may lead to authorization denial.

Denial Risk

Safety signal — higher post-injection pain and NNH ~13 for PRP (foot/ankle)

Systematic reviews of foot and ankle PRP trials report higher rates of post-injection pain and calculate a number needed to harm of 13 for PRP; this safety signal (injection-site pain) may influence medical necessity determinations.

Denial Risk

Uncertain protocols — absence of optimal PRP methods may lead to denial

Uncertain and heterogeneous PRP protocols and unclear optimal preparation/application increase uncertainty about which patients benefit; lack of protocol clarity in documentation may lead to coverage denial.

Denial Risk

Wound indication risk — inconclusive evidence may prompt denial

Evidence for autologous PRP in chronic wounds is inconclusive and often low quality; for wound indications outside limited DFU findings, lack of strong evidence may trigger coverage denial.

Denial Risk

Knee OA governance requirement — use only under governance/research arrangements

NICE recommends PRP for knee osteoarthritis only with special arrangements for governance, consent, and audit or research; absence of such arrangements or documentation may result in noncoverage.

Denial Risk

Plan terms govern — contractual/federal/state rules determine coverage

Coverage decisions must follow federal, state, or contractual benefit plan terms; if plan terms do not permit coverage for these unproven therapies, requests will be denied regardless of clinical documentation.

Procedure and Billing Codes

Procedure/CPT/HCPCS Codes Listedmixed

0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
M0076	Prolotherapy.
P9020	Platelet rich plasma, each unit

Definitions and Terminology

Prolotherapy 68: definition and intent

DefinitionProlotherapy (proliferative therapy) — an injection-based orthopedic procedure that introduces a substance (e.g., dextrose, saline, sarapin, procaine, or lidocaine) at a directed injury site to stimulate a mild inflammatory response and promote growth of normal ligament, tendon, or joint tissue to strengthen and repair injured structures.

IntentStimulate the body’s healing processes to lay down new tissue in weakened areas, producing gradual tissue buildup and tightening of structures to reduce pain and improve function.

Common agentsDextrose (hypertonic), saline, local anesthetics (procaine, lidocaine), sarapin; newer formulas may include PRP or autologous stem cell sources.

Mechanism describedA directed injection 'tricks' the body by creating a mild inflammatory response that encourages growth of new ligament or tendon fibers and progressive restoration of strength with repeated treatments.

PRP 69: definition and description

DefinitionPlatelet-rich plasma (PRP) — an autologous blood-derived preparation with a high platelet concentration containing platelet-derived growth factors and cytokines intended to stimulate regeneration and promote tissue repair when injected into soft tissues or joints.

Preparation variabilityPRP preparations are not standardized and show wide variability in platelet and white blood cell concentrations, activation methods, volume, and other parameters.

Primary rationaleIntroduce concentrated platelets/growth factors to tissues with low healing potential to promote regeneration and tissue repair.

Safety/efficacy noteEvidence is heterogeneous; limited long-term safety and efficacy data beyond one year and higher-quality studies with standardized protocols are needed.

Dextrose Prolotherapy (DPT / HDP / PrT) 70: definition and concentration ranges

DefinitionDextrose Prolotherapy (DPT / HDP / PrT) — injection-based therapy using hypertonic dextrose solutions administered intra-articularly, peri-articularly, peri‑tendinously or perineurally to reduce pain and improve function by a proliferative/inflammatory mechanism.

Concentration ranges reportedConcentrations reported across studies include low (5%), mid (15%), and high (up to 50%) dextrose solutions; trials commonly used values such as 5%, 15%, 20%, and 50% depending on indication and technique.

Typical administration sitesIntra-articular (e.g., knee), peri‑articular/enthesis (e.g., lateral epicondyle), peri‑tendinous and perineural targets depending on diagnosis.

HA plus dextrose co-injection 71: definition

DefinitionHA plus dextrose co-injection — combination intra-articular injection of hyaluronic acid together with hypertonic dextrose intended as an adjunct to improve pain, physical function, and performance measures compared with HA plus saline co-injection.

Evidence noteA randomized trial reported HA plus dextrose co-injections produced greater improvements in stair-climbing time and WOMAC physical function through 6 months versus HA plus normal saline.

Dextrose Prolotherapy (DPT) 72: injection targets and technique variability

Injection targetsDPT targets entheses and peri‑tendinous regions (e.g., lateral epicondyle, supraspinatus tendon), intra-articular spaces (e.g., knee), and perineural/periarticular sites based on the clinical diagnosis.

Technique variabilityUltrasound guidance is used in many trials; number of injections, intervals (weekly to monthly), and combination of intra‑ and peri‑articular injections vary by study and indication.

Prolotherapy (DPT) 73: hyperosmolar dextrose description

DescriptionHyperosmolar dextrose (DPT) is an injection therapy using hypertonic dextrose/glucose solutions that produce a local inflammatory/proliferative response to encourage tissue repair in periarticular, intra‑articular, or tendon tissues.

Clinical effects reportedSmall RCTs and systematic reviews report short-term pain and functional improvements (e.g., in TMJ, lateral epicondylitis, shoulder tendinopathy), though effects are often not sustained and studies have short follow-up.

Adverse eventsReported AEs are generally limited to transient injection-site pain and ecchymosis resolving within weeks in published trials.

PRP 74: autologous blood-derived concentrate definition and preparation variability

DefinitionAutologous blood-derived concentrate prepared from the patient’s own blood that concentrates platelets and associated growth factors for injection into joints or soft tissue.

Preparation variabilityPreparation methods vary widely across studies (platelet concentration, leukocyte content, centrifugation and activation steps, and reported cell counts are often inconsistent or unreported).

Clinical implicationLack of standardization in PRP preparation complicates comparison across studies and interpretation of efficacy and safety outcomes.

Leukocyte-rich vs leukocyte-poor PRP 75: distinction and potential adverse event differences

DistinctionLeukocyte-rich (LR) PRP contains higher white blood cell counts compared with leukocyte-poor (LP) PRP; studies categorize PRP by leukocyte content as an important preparation variable.

Adverse event differencesSome reports and meta-analyses note more local adverse events (eg, post-injection pain) with leukocyte-rich PRP compared with leukocyte-poor PRP.

Efficacy uncertaintyEfficacy differences between LR and LP PRP are not consistently established due to heterogeneity and limited reporting in trials.

PRP heterogeneity 76: sources of variation across studies

Sources of variationPRP heterogeneity arises from differences in platelet concentration, leukocyte content, activation method, centrifugation protocol, injected volume, number/timing of injections, and use of imaging guidance.

Impact on evidenceThese sources of variation contribute to inconsistent outcomes across RCTs and systematic reviews and limit generalizability of study results.

Reporting gapMany studies do not report standardized platelet/WBC counts or growth factor quantification, complicating synthesis and reproducibility.

Autologous PRP 77: definition and study reporting gaps

DefinitionAutologous PRP — a blood product derived from the patient’s own blood that concentrates platelets and associated growth factors for therapeutic injection.

Common reporting gaps in trialsMany studies fail to report composition details (platelet and WBC counts, growth factor measurements), activation methods, and standardized preparation steps.

ConsequencesIncomplete reporting of PRP composition and preparation undermines interpretation of efficacy and safety and hinders reproducibility across clinical settings.

PRP / Prolotherapy regulation note 78: devices vs procedures regulatory context

Regulatory contextPRP and prolotherapy are procedural therapies and are not themselves subject to FDA regulation; devices, drugs, biologics, or tests used as part of these procedures may be regulated by the FDA.

Off-label use noteAgents used (eg, dextrose, lidocaine) are FDA-approved for injection generally but are not specifically FDA-approved for prolotherapy indications, making such uses off-label.

prolotherapy / hypertonic dextrose 79: concise definition

Concise definitionProlotherapy / hypertonic dextrose — injection of hypertonic dextrose solution into periarticular, peri‑tendinous, or intra‑articular tissues to provoke a local proliferative/inflammatory response intended to stimulate healing and reduce pain.

Typical concentrationsConcentrations commonly reported include 5%, 15%, 20%, and higher up to 50% depending on indication and protocol.

Usual adverse eventsTransient injection-site pain and ecchymosis are commonly reported and typically resolve within weeks.

platelet-rich plasma (PRP) / platelet-rich fibrin (PRF) 80: concise definition

Concise definitionPlatelet-rich plasma (PRP) / platelet-rich fibrin (PRF) — autologous platelet-derived biologic injections that concentrate platelets and growth factors from the patient’s blood to promote tissue regeneration in soft-tissue and intra‑articular indications.

Heterogeneity notePRP/PRF products and preparation methods vary widely across studies (platelet/WBC content, activation, centrifugation), limiting comparability of results.

Clinical evaluationEvaluated in randomized trials and meta-analyses across knee osteoarthritis, tendinopathies, wound healing, and surgical augmentation with mixed and inconsistent results.

Background and Evidence Context

Prolotherapy encompasses injection of hypertonic dextrose or other irritant solutions intended to stimulate local healing and tissue proliferation. PRP is an autologous blood-derived concentrate of platelets and growth factors used intra‑articularly or in soft tissues; both therapies are procedural and lack standardized preparation methods, which contributes to heterogeneity in study results and uncertainty regarding efficacy and safety.

Policy Revision History

2026-02-01policy_revisionLatest

Updated Clinical Evidence and References sections; archived previous policy version CS103TN.S.